Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × HCC × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 202 Carcinoma, Non-Small-Cell Lung 191 Prostatic Neoplasms 155 Multiple Myeloma 102 Colorectal Neoplasms 96 Neoplasms 92 Squamous Cell Carcinoma of Head and Neck 87 Leukemia, Myeloid, Acute 83 Neoplasm Metastasis 80 Lung Neoplasms 76 Melanoma 73 Pancreatic Neoplasms 65 Ovarian Neoplasms 63 Triple Negative Breast Neoplasms 59 Carcinoma, Hepatocellular 59 Recurrence 57 Leukemia, Lymphocytic, Chronic, B-Cell 54 Brain Neoplasms 54 Lymphoma 50 Glioblastoma 50 Carcinoma, Renal Cell 48 Urinary Bladder Neoplasms 43 Sarcoma 42 Endometrial Neoplasms 41 Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Lymphoma, Large B-Cell, Diffuse 39 Stomach Neoplasms 38 Head and Neck Neoplasms 38 Uterine Cervical Neoplasms 37 Rectal Neoplasms 37

Interventions

atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡